Aclaris Therapeutics (ACRS)
(Delayed Data from NSDQ)
$1.91 USD
-0.04 (-2.05%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $1.88 -0.03 (-1.57%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
ACRS 1.91 -0.04(-2.05%)
Will ACRS be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ACRS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ACRS
Strength Seen in Xencor (XNCR): Can Its 7.3% Jump Turn into More Strength?
Aclaris Therapeutics (ACRS) Reports Q2 Loss, Beats Revenue Estimates
ACRS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Harrow (HROW) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Aclaris Therapeutics (ACRS) Expected to Beat Earnings Estimates: Should You Buy?
Aclaris Therapeutics (ACRS) Reports Q1 Loss, Misses Revenue Estimates
Other News for ACRS
200 Day Moving Average Support appears for ACRS after 2.05% move
ACRS Crossed Above 20 Day Moving Average on September 19
New Downtrend appears for ACRS after 1.63% move
Doji - Bullish? appears for ACRS after 0.0% move
Fell Below 20 Day Moving Average appears for ACRS after 5.64% move